{"id":"telmisartan-amlodipine-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"null","effect":"Edema"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Telmisartan works by blocking the action of angiotensin II, a potent vasoconstrictor, which leads to vasodilation and reduced blood pressure. Amlodipine blocks the influx of calcium ions into smooth muscle cells, causing vasodilation and reduced blood pressure. Hydrochlorothiazide increases the excretion of sodium and water, leading to decreased blood volume and reduced blood pressure.","oneSentence":"Telmisartan is an angiotensin II receptor antagonist, while amlodipine is a calcium channel blocker, and hydrochlorothiazide is a thiazide diuretic.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:54.474Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Chronic stable angina"}]},"trialDetails":[{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT02373163","phase":"PHASE4","title":"INTERVENCION Trial","status":"COMPLETED","sponsor":"Prevencion","startDate":"2014-09-01","conditions":"Blood Pressure, High","enrollment":166},{"nctId":"NCT03205137","phase":"","title":"Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-06-01","conditions":"Hypertension","enrollment":""},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT03021265","phase":"","title":"To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-01-20","conditions":"Hypertension","enrollment":676},{"nctId":"NCT03889145","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-12-19","conditions":"Healthy","enrollment":30},{"nctId":"NCT01996085","phase":"NA","title":"Non-invasive Haemodynamic Assessment in Hypertension","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2013-01","conditions":"Arterial Hypertension","enrollment":144},{"nctId":"NCT02121535","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-04","conditions":"Healthy","enrollment":72},{"nctId":"NCT02129192","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT03032315","phase":"PHASE1","title":"Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-10-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT02739672","phase":"PHASE1","title":"Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-01-02","conditions":"Healthy","enrollment":40},{"nctId":"NCT02183675","phase":"PHASE1","title":"Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT01975246","phase":"PHASE3","title":"Add-on to Micamlo BP Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Hypertension","enrollment":309},{"nctId":"NCT02738632","phase":"PHASE3","title":"Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-05","conditions":"Essential Hypertension","enrollment":300},{"nctId":"NCT00509470","phase":"PHASE4","title":"Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":75},{"nctId":"NCT01911780","phase":"PHASE3","title":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07","conditions":"Hypertension","enrollment":132},{"nctId":"NCT01819220","phase":"PHASE4","title":"Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-04","conditions":"Hypertension","enrollment":16},{"nctId":"NCT00240474","phase":"PHASE4","title":"A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-12","conditions":"Hypertension","enrollment":1000},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT01180205","phase":"PHASE4","title":"Telmisartan, Amlodipine and Flow Mediated Dilation","status":"UNKNOWN","sponsor":"Johannes Gutenberg University Mainz","startDate":"2010-08","conditions":"Hypertension","enrollment":576},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Telmisartan/Amlodipine+Hydrochlorothiazide","genericName":"Telmisartan/Amlodipine+Hydrochlorothiazide","companyName":"IlDong Pharmaceutical Co Ltd","companyId":"ildong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telmisartan is an angiotensin II receptor antagonist, while amlodipine is a calcium channel blocker, and hydrochlorothiazide is a thiazide diuretic. Used for Hypertension, Chronic stable angina.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}